title: Atrial fibrillation: epidemiology, mechanisms and management.
abstract: The incidence of AF, the most common sustained arrhythmia in clinical practice, increases with age and coronary artery disease, hypertension and valvular heart disease are common underlying substrates; however, occasionally, AF may occur without any underlying heart disease. The most widely accepted theory of its mechanism is Moe's multiple wavelet hypothesis, although recent studies are helping to shed light on other mechanisms, including the focal origin of AF in some patients. Most patients experience palpitations, but fatigue, dyspnoea, and dizziness may also occur. Therapy includes prevention of thromboembolism, control of rate, and restoration and maintenance of sinus rhythm. The risks and benefits of each treatment modality need to be assessed according to each patient's circumstances. Unlike other arrhythmias, there is still no highly successful therapy for treating AF. However, significant advances are being made using non-pharmacological approaches to either prevent or cure this troublesome arrhythmia.
authors.affiliation: Electrophysiology Laboratories, St Luke's Medical Centre, University of Wisconsin Medical School, Milwaukee, USA.
authors.forename: A
authors.initials: A
authors.lastname: Bhatia
authors.forename: J
authors.initials: J
authors.lastname: Sra
mesh_terms: D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable; D006801:Humans; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D013177:Sports; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D000638:Amiodarone